Early lenalidomide treatment for low and intermediate‐1 International Prognostic Scoring System risk myelodysplastic syndromes with del(5q) before transfusion dependence

Lenalidomide is approved for the treatment of transfusion‐dependent (TD) del(5q) myelodysplastic syndromes (MDS). However, few data are available in patients with transfusion‐independent (TI) del(5q) MDS. In the first, observational, part of this 2‐part study, we assessed the impact of transfusion d...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Cancer Med
Главные авторы: Oliva, Esther N., Lauseker, Michael, Aloe Spiriti, Maria Antonietta, Poloni, Antonella, Cortelezzi, Agostino, Palumbo, Giuseppe A., Balleari, Enrico, Sanpaolo, Grazia, Volpe, Antonio, Ricco, Alessandra, Ronco, Francesca, Alati, Caterina, D'Errigo, Maria Grazia, Santacaterina, Irene, Kündgen, Andrea, Germing, Ulrich, Latagliata, Roberto
Формат: Artigo
Язык:Inglês
Опубликовано: John Wiley and Sons Inc. 2015
Предметы:
Clinical Cancer Research
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5123712/
https://ncbi.nlm.nih.gov/pubmed/26376955
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.523
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы